BACKGROUND: Some mutations of androgen receptor (AR) confer resistance to antiandrogen to prostate cancer (PC) cells. Previously we reported that LNCaP-cxD2 cells established from androgen-dependent LNCaP-FGC PC cells as an antiandrogen bicalutamide-resistant subline harbor W741C/L mutation in the AR gene. In this report, we examined one possible mechanism of the resistance. METHODS: Change in the gene expression and the protein levels relevant to mutagenesis in LNCaP-FGC cells during bicalutamide-treatment was assessed. The AR sequence of bicalutamide-resistant LNCaP-cxD2 cells was compared with that of parental LNCaP-FGC cells. RESULTS: The expression of DNA polymerases (Pol) switched from high-fidelity subset to error-prone subset, and DNA mismatch repair proteins (MMR) were down-regulated. The rate of multiple mutations in the AR gene was higher in LNCaP-cxD2 cells than LNCaP-FGC cells. CONCLUSIONS: These results suggest the hypermutational state might occur in LNCaP-FGC cells during bicalutamide-treatment, which might create the W741C/L mutant AR leading to bicalutamide-resistance. Copyright 2005 Wiley-Liss, Inc
BACKGROUND: Some mutations of androgen receptor (AR) confer resistance to antiandrogen to prostate cancer (PC) cells. Previously we reported that LNCaP-cxD2 cells established from androgen-dependent LNCaP-FGC PC cells as an antiandrogen bicalutamide-resistant subline harbor W741C/L mutation in the AR gene. In this report, we examined one possible mechanism of the resistance. METHODS: Change in the gene expression and the protein levels relevant to mutagenesis in LNCaP-FGC cells during bicalutamide-treatment was assessed. The AR sequence of bicalutamide-resistant LNCaP-cxD2 cells was compared with that of parental LNCaP-FGC cells. RESULTS: The expression of DNA polymerases (Pol) switched from high-fidelity subset to error-prone subset, and DNA mismatch repair proteins (MMR) were down-regulated. The rate of multiple mutations in the AR gene was higher in LNCaP-cxD2 cells than LNCaP-FGC cells. CONCLUSIONS: These results suggest the hypermutational state might occur in LNCaP-FGC cells during bicalutamide-treatment, which might create the W741C/L mutant AR leading to bicalutamide-resistance. Copyright 2005 Wiley-Liss, Inc
Authors: Christine Pybus; Mario Pedraza-Reyes; Christian A Ross; Holly Martin; Katherine Ona; Ronald E Yasbin; Eduardo Robleto Journal: J Bacteriol Date: 2010-04-30 Impact factor: 3.490
Authors: Yoshitsugu Mitani; Pulivarthi H Rao; Sankar N Maity; Yu-Chen Lee; Renata Ferrarotto; Julian C Post; Lisa Licitra; Scott M Lippman; Merrill S Kies; Randal S Weber; Carlos Caulin; Sue-Hwa Lin; Adel K El-Naggar Journal: Clin Cancer Res Date: 2014-10-14 Impact factor: 12.531
Authors: Timothy A Yap; Alan D Smith; Roberta Ferraldeschi; Bissan Al-Lazikani; Paul Workman; Johann S de Bono Journal: Nat Rev Drug Discov Date: 2016-07-22 Impact factor: 84.694
Authors: Luis Cisneros; Kimberly J Bussey; Adam J Orr; Milica Miočević; Charles H Lineweaver; Paul Davies Journal: PLoS One Date: 2017-04-25 Impact factor: 3.240
Authors: David Quinto-Alemany; Ana Canerina-Amaro; Luís G Hernández-Abad; Félix Machín; Floyd E Romesberg; Cristina Gil-Lamaignere Journal: PLoS One Date: 2012-07-31 Impact factor: 3.240